EconomyTop Interview: Daiichi Sankyo CEO Reflects on Delayed Results and the Cost of Success

Daiichi Sankyo is pursuing a goal of becoming one of the world’s top five companies in oncology by 2035, propelled by the success of Enhertu. Its oncology revenue reached ¥954 billion, while the company is expanding a proprietary DXd-ADC platform with seven ADC product groups, including candidates in clinical development.

Daiichi Sankyocancer drugsEnhertuADC

TToyo Keizai★★☆☆☆2026-08-06 20:50Original